Cargando…

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

OBJECTIVE: Cannabidiol (CBD) has been approved by the US Food and Drug Administration (FDA) to treat intractable childhood epilepsies, such as Dravet syndrome and Lennox‐Gastaut syndrome. However, the intrinsic anticonvulsant activity of CBD has been questioned due to a pharmacokinetic interaction b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anderson, Lyndsey L., Absalom, Nathan L., Abelev, Sarah V., Low, Ivan K., Doohan, Peter T., Martin, Lewis J., Chebib, Mary, McGregor, Iain S., Arnold, Jonathon C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Full‐length Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900043/ https://www.ncbi.nlm.nih.gov/pubmed/31625159 http://dx.doi.org/10.1111/epi.16355

Ejemplares similares

Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials
por: Gunning, Boudewijn, et al.
Publicado: (2020)

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials
por: Devinsky, Orrin, et al.
Publicado: (2020)

Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy
por: Anderson, Lyndsey L., et al.
Publicado: (2021)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults
por: Chughlay, M. Farouk, et al.
Publicado: (2022)

Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial
por: Zamarripa, C. Austin, et al.
Publicado: (2023)

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence
por: Arnold, Jonathon C., et al.
Publicado: (2022)

A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam
por: Tolbert, Dwain, et al.
Publicado: (2018)

Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses
por: Umpierrez, Laísa S., et al.
Publicado: (2022)

An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma
por: Colvin, Emily K., et al.
Publicado: (2022)

Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial
por: McCartney, Danielle, et al.
Publicado: (2022)

Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid‐dependent, human immunodeficiency virus seronegative participants
por: Moore, Katy, et al.
Publicado: (2019)

Clobazam and Its Use in Epilepsy
por: Pernea, Marius, et al.
Publicado: (2016)

A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam
por: VanLandingham, Kevan E., et al.
Publicado: (2020)

The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia
por: Ralvenius, William T., et al.
Publicado: (2016)

A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
por: Morrison, Gilmour, et al.
Publicado: (2019)

Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years
por: Conry, Joan A, et al.
Publicado: (2014)

Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial
por: Sahinovic, Ayshe, et al.
Publicado: (2022)

Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice
por: Long, Leonora E., et al.
Publicado: (2012)

Hypothermia associated with clobazam use in adult epilepsy
por: Gauthier, Angela C., et al.
Publicado: (2016)

Effects of clobazam for treatment of refractory status epilepticus
por: Madžar, Dominik, et al.
Publicado: (2016)

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)

Clinical Pharmacokinetics and Pharmacodynamics of Propofol
por: Sahinovic, Marko M., et al.
Publicado: (2018)

CLOBAZAM SINGLE OR DIVIDED DOSE AGAINST DIAZEPAM IN ANXIETY NEUROSIS
por: Channabasavanna, S.M., et al.
Publicado: (1986)

ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice
por: Brzozowska, Natalia, et al.
Publicado: (2016)

Effect of clobazam as add-on antiepileptic drug in patients with epilepsy
por: Joshi, Rupa, et al.
Publicado: (2014)

Systematic review of clobazam use in patients with status epilepticus
por: Mahmoud, Sherif Hanafy, et al.
Publicado: (2018)

Effect of plasmapheresis on serum levels of clobazam, levetiracetam and topiramate
por: Hau Man, To Harmony, et al.
Publicado: (2017)

Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
por: Jang, Kyungho, et al.
Publicado: (2017)

Clobazam as an adjunctive therapy in treating seizures associated with Lennox–Gastaut syndrome
por: Leahy, Jennifer T, et al.
Publicado: (2011)

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric  Oxyhydroxide
por: Cozzolino, Mario, et al.
Publicado: (2014)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2021)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2020)

Beyond CBD: Inhibitory effects of lesser studied phytocannabinoids on human voltage-gated sodium channels
por: Milligan, Carol J., et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine
por: Weerink, Maud A. S., et al.
Publicado: (2017)

Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans
por: Jakate, Abhijeet, et al.
Publicado: (2020)

A CONTROL CLINICIAL TRIAL OF A NEW ANXIOLYTIC ‘CLOBAZAM’
por: Singh, Gurmeet, et al.
Publicado: (1984)

Clobazam: The phoenix drug (from the very old to the brand new)
por: Guerreiro, Carlos A. M.
Publicado: (2014)

Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20)
por: Lintzeris, Nicholas, et al.
Publicado: (2022)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019)

Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations
por: Anderson, Lyndsey L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9675i2ssqhmpfosslv52skv84d